International Journal of Immunopathology and Pharmacology · 2021 · 47 citations · 12 references
Life SciencesInfectious DiseasesMicrobiologyDiagnostic MicrobiologyInfectious Disease PharmacotherapyMedical MicrobiologyOral ProbioticsProbioticsBifidobacterium-based Oral ProbioticsMortality Rate ComparisonProbiotic Effects On Gut MicrobiotaProbiotic MicroorganismsSafety Of Oral ProbioticsSars-cov-2 InfectionTolerability Of Oral Probiotics
on moderate/severe SARS-CoV-2 inpatients. In this single-center study, we analyzed data of 44 moderate/severe inpatients with diagnosed COVID-19 in Istanbul Maltepe University Medical Faculty Hospital, 2020 from 1 November 2020 to 15 December 2020. Clinical and medication features were compared and analyzed between patients with or without probiotic. In result, 19 of the 44 patients (43.18%) who were administrated with oral booster-single strain probiotic were discharged with the median inpatient day of 7.6 days which were significantly shorter than those of patients without probiotic. There were significant differences in inpatient days, radiological improvement at day 6 and week 3, and reduction in interleukin-6 levels in those receiving oral probiotic therapy. Although the mortality rate was 5% in the probiotic group, it was 25% in the non-probiotic group. Booster-single strain probiotic bifidobacteria could be an effective treatment strategy for moderate/severe SARS-CoV-2 inpatients to reduce the mortality and length of stay in hospital.
12
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Hongzhou Lu · BioScience Trends · 2020 · 1.2K citations · Full text
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Iván O. Rosas, Norbert Bräu, Michael R. Waters et al. · New England Journal of Medicine · 2021 · 1.1K citations · Full text
Analysis of Serum Cytokines in Patients with Severe Acute Respiratory Syndrome
Yuanchun Zhang, Jing Li, Yuliang Zhan et al. · Infection and Immunity · 2004 · 356 citations · Full text